CureVac NV (CVAC)
3.33
-0.15
(-4.31%)
USD |
NASDAQ |
Jun 18, 10:13
CureVac Cash from Investing (Quarterly): -5.527M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -5.527M |
| December 31, 2023 | -15.35M |
| September 30, 2023 | -14.57M |
| June 30, 2023 | -15.71M |
| March 31, 2023 | -14.14M |
| December 31, 2022 | -25.51M |
| September 30, 2022 | -25.46M |
| June 30, 2022 | -28.35M |
| Date | Value |
|---|---|
| March 31, 2022 | -19.28M |
| December 31, 2021 | -41.32M |
| September 30, 2021 | -21.17M |
| June 30, 2021 | -45.01M |
| March 31, 2021 | -43.83M |
| March 31, 2020 | -3.663M |
| March 31, 2019 | 19.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-45.01M
Minimum
Jun 2021
-3.663M
Maximum
Mar 2020
-22.78M
Average
-20.23M
Median
Cash from Investing (Quarterly) Benchmarks
| BioNTech SE | -2.503B |
| Affimed NV | -0.0011M |
| Moderna Inc | 118.00M |
| InflaRx NV | 29.27M |
| MorphoSys AG | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -104.88M |
| Cash from Financing (Quarterly) | -1.221M |
| Free Cash Flow | -339.08M |
| Free Cash Flow Per Share (Quarterly) | -0.4922 |
| Free Cash Flow to Equity (Quarterly) | -110.40M |
| Free Cash Flow to Firm (Quarterly) | -110.40M |
| Free Cash Flow Yield | -45.45% |